Los Angeles-based nutrition technology company L-Nutra announced a $36.5 million investment in its Series D funding round led by Mubadala. The company works to make scientific advancements in nutrition for longevity and nutrition as medicine. Its latest investment brings L-Nutra’s Series D to $83.5 million.
The company spearheads discovery, design and commercialization programs geared toward enhancing the human healthspan and driving remission in chronic diseases. L-Nutra has conducted 47 clinical trials and been granted 137 patents to leverage nutrition to maximize safety, nourishment and therapeutic benefit across the globe.
“We are on the cusp of enhancing human healthspan, adding years to our life and life to our years,” Joseph Antoun, L-Nutra’s chairman and CEO, said in a statement. “…. We have spent decades advancing nutrition R&D and developing effective interventions that can be integrated within our healthcare system. By reformulating food into clinically validated nutrition programs, we now can support patients and individuals seeking to embark on a healthy longevity journey.”
The new injection of capital enables L-Nutra to launch a joint operation with Mubadala in Abu Dhabi to produce medical nutrition therapies and longevity nutrition for populations in the Middle East and North Africa.
